Posts tagged “1800 Public Relations”

President & CEO Leen Kawas, PhD of M3 Biotechnology, Inc. to Be Interviewed Live on Clear Channel’s “The Trader’s Network Show”

Live Interview to Air March 14th 2015 hosted by Michael Yorba, 1:30pm ET/10:30am PT/12:30pm CT

SEATTLE, WA–(Mar 13, 2015) – Leen Kawas, Ph.D, CEO of an innovative young therapeutics company named M3 Biotechnology, Inc., that has a novel platform of drugs which could reverse the course of neurodegenerative diseases like Parkinson’s Disease and Alzheimer’s by inducing brain cells to grow again, will be interviewed on a Clear Channel iHeart Business Radio’s live worldwide stream.

Kawas will be interviewed live on Saturday, March 14, 2015, at 1:30 p.m. ET by host Michael Yorba on “The Trader’s Network,” to discuss M3’s growth-factor-modifying pharmaceuticals platform that has begun to attract significant interest having completed animal trials and now moving toward human trials.

We encourage all shareholders, analysts, industry professionals and interested parties to tune in live. The details and link to iHeart Radio’s live worldwide steam are below.

Date: March 14, 2015
Start Time: 1:30pm ET | 10:30am PT | 12:30pm CT
Network: Clear Channel/ iHeart Radio
Station: DFW 1190AM KFXR
KFXR Show: The Traders Network Show
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more information visit its website at www.clearchannel.com.

About The Traders Network Show
For the past six years “The Traders Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 7am – 8am, Monday-Friday and Saturdays from 1pm – 3pm ET. Host Michael Yorba interviews the front-page titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and investment insights in a new light and keeps audiences asking for more… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Traders Network Show.

About President and CEO Leen Kawas, PhD.
The young firm where Kawas became CEO on late 2013 has developed a drug, now moving toward initial human trials, a drug that would not merely slow but actually reverse the course of neurodegenerative diseases like Parkinson’s Disease and Alzheimer’s. Dr. Kawas was co-inventor of the drug and co-founder of M3.

In addition to co-inventing the drug MM-201 and guiding the company toward its funding goals, M3’s scientist has successfully obtained grant-funding from noteworthy national organizations like the National Institutes of Health, the Alzheimer’s Drug Discovery Fund and the Michael J. Fox Foundation and impressive grant support from the Life Science Discovery Fund in Washington State.

M3’s drug is not merely a novel technology to addressing the neurodegenerative diseases but the approach for which she plans to seek FDA approval is also novel, taking advantage of a fast-track designation the FDA has approved to dramatically reduce the time and data required to enhance efficiency in getting drugs to market.

Kawas unique combination of scientific and medical knowledge, starting her career as a clinical pharmacist and then getting her PhD in molecular Pharmacology, give her the credibility to lead the company in its next research-intensive phase. While growing the company’s science and licensing the technology out of Washington State University, Kawas was also able to raise more than $2 million from both dilutive and non-dilutive sources, including grants from the National Institute of Health (NIH), Alzheimer’s Drug Discovery and Michael J Fox Foundations, to support development of the therapeutics being advanced in M3, especially MM-201. Dr. Kawas’ goal and passion is entrepreneurship that leads to disease modifying pharmaceuticals that address critical unmet medical needs. And as a female entrepreneur with a scientific background, Kawas is committed to mentoring women in science and business and has been selected for programs to inspire women to go into those fields, and was featured as a role model for women in a profile recently in a Spokane, WA business magazine. For Kawas, the challenge of raising investment capital for her start-up company while overcoming the array of obstacles facing a 29-year-old Middle Eastern female are more than offset by the successes she has been able to achieve.

About M3 Biotechnology, Inc.
M3 is preparing for a Phase I clinical trial of its patented small molecule therapy, MM-201. MM-201 is an orally delivered drug that causes stem cells to differentiate into neuron cells at a rate faster than degenerative brain diseases, such as Parkinson’s and Alzheimer’s, destroys them. During this trial, it is expected that M3 will enter into a license agreement with one of six large pharmaceutical companies to complete the FDA approval process and prepare for commercially manufacturing and marketing the drug. As a disease modifying and feasibly delivered drug, it is expected that MM201 will become the standard of care for patients afflicted with these diseases.

MM-201, with its first-in-class growth actor-activation process and unique small-molecule characteristic, which represents an important opportunity for potential investors as M3 raises the funds necessary to enable MM-201 to move through human trials and to market. The uniqueness of MM-201 is that it is orally available, able to permeate the protective blood brain barrier and thus modify the effects of Parkinson’s disease (PD) and Alzheimer’s disease (AD).

M3’s initial development work has been supported by grants from both the Michael J. Fox Foundation and the Alzheimer’s Drug Discovery Foundation, Life Science Discovery fund financial support stemming from the understanding of those foundations of the novel paradigm that M3’s technology represents. This support shows the understanding that M3’s technology could, for the first time in a non-invasive way as compared to Deep Brain Stimulation and other technologies in the pipeline, stop and possibly reverse the clinical course of these diseases. In addition to the life-altering potential of this drug, success would quickly lead to domination in a multi-billion dollar market.

The drug has demonstrated efficacy in numerous animal models of neurodegenerative disease (NDD) including the rat scopolamine dementia model, the aged rat dementia model and the Rat 6-OHDA model of PD.

A 1800PublicRelations.com PR Event…

CONTACT INFORMATION

CEO & Chairman Ted William Karkus of ProPhase Labs, Inc. to Be Interviewed Live on Clear Channel – iHeart Business Talk Radio’s “Health Tech Talk Live”

Live Interview Airs Saturday, February 28th, 2015, 3:00pm ET/12:00pm PT/2:00pm CT

DOYLESTOWN, PA–(Feb 27, 2015) – ProPhase Labs, Inc. (NASDAQ: PRPH), a company that engages in the manufacture, marketing, and distribution of homeopathic and health products to the general public, announced today that CEO & Chairman Ted William Karkus will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM this Saturday at 3:00pm ET. In this exclusive 2-segment interview, Mr. Karkus will discuss the research and development of over-the-counter (OTC) drugs, natural base health products with supplements, personal care and cosmeceutical products. We encourage investors, analysts, industry professionals and all interested parties to tune in and listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: February 28, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: Health Tech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE

About ProPhase Labs, Inc.
ProPhase Labs is a diversified natural health medical science company. It is a leading marketer of the Cold-EEZE® Cold Remedy brand as well as other cold relief products. Cold-EEZE®Cold Remedy zinc gluconate lozenges are clinically proven to significantly reduce the duration of the common cold. Cold-EEZE® Cold Remedy customers include leading national retailers, chain food, drug and mass merchandise stores, wholesalers and distributors, as well as independent pharmacies. ProPhase Labs has several wholly owned subsidiaries including a manufacturing unit, which consists of an FDA registered facility to manufacture Cold-EEZE®Cold Remedy lozenges and fulfill other contract manufacturing opportunities. For more information visit us at www.ProPhaseLabs.com.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About HealthTech Talk Live
HealthTech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s HealthTech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on HealthTech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

Forward Looking Information
Except for the historical information contained herein or discussed on air on February 28, 2015, this document and our on-air discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of the acceptance and demand for our products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any subsequent SEC filings.

Aradigm Corporation President & CEO Dr. Igor Gonda, Ph.D. to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM’s “Health Tech Talk Live”

Live Interview to Air on February 28th, 2015, Hosted by Ben Chodor, 3:00pm ET/12:00pm PT/2:00pm CT

HAYWARD, CA–(Feb 27, 2015) – Aradigm Corporation (NASDAQ: ARDM), a company actively engaged in fulfilling the promise of developing inhalation drug products that could revolutionize the quality of life of patients with severe pulmonary disease, announced today that President and Chief Executive Officer (CEO) Dr. Igor Gonda, Ph.D. will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM tomorrow, at 3:00pm ET. In this exclusive double-segment interview, Dr. Gonda will discuss how the company has attracted an outstanding team of scientists, engineers and clinical experts who have been at the forefront of development of advanced inhalation delivery products like AERx®, a pulmonary delivery platform.

Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: February 28, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: Health Tech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE 

About Aradigm Corporation
Aradigm is actively engaged in fulfilling the promise of developing inhalation drug products that could revolutionize the quality of life of patients with severe pulmonary disease.

Since 1991, the company has attracted an outstanding team of scientists, engineers and clinical experts who have been at the forefront of development of advanced inhalation delivery products. This team for example, pioneered the AERx® pulmonary delivery platform that was tested in thousands of patients with drugs and biologics including insulin, fentanyl, erythropoietin and nicotine. With the depth of experience and expertise in inhalation delivery, Aradigm is uniquely positioned to develop a portfolio of its own products to treat patients with severe respiratory diseases. The current pipeline includes an inhaled antibiotic being developed for the treatment of bronchiectasis*, cystic fibrosis and for biodefense, and inhaled nicotine for smoking cessation.

About President and CEO Dr. Igor Gonda, Ph.D.
Dr. Gonda has served as President and Chief Executive Officer since August 2006, and as a director since September 2001. From December 2001 to August 2006, Dr. Gonda was the Chief Executive Officer and Managing Director of Acrux Limited, a publicly traded specialty pharmaceutical company located in Melbourne, Australia. From July 2001 to December 2001, Dr. Gonda was our Chief Scientific Officer and, from October 1995 to July 2001, was our Vice President, Research and Development. From February 1992 to September 1995, Dr. Gonda was a Senior Scientist and Group Leader at Genentech, Inc. leading inhalation development of products for severe respiratory disease. Prior to that, Dr. Gonda held academic positions at the University of Aston in Birmingham, United Kingdom, and the University of Sydney, Australia. Dr. Gonda holds a B.Sc. in Chemistry and a Ph.D. in Physical Chemistry from Leeds University, United Kingdom. Dr. Gonda was the Chairman of our Scientific Advisory Board until August 2006.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About Health Tech Talk Live
Health Tech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s Health Tech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on Health Tech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

1800PublicRelations.com PR Event…

Chairman & CEO Rik J. Deitsch of Nutra Pharma Corporation to Be Interviewed Live on iHeart Radio / Clear Channel Atlanta Studios – 640 WGST AM’s “Health Tech Talk Live”

Live Interview to Air February 21, 2015, Hosted by Ben Chodor, 3:00pm ET/12:00pm PT/2:00pm CT

CORAL SPRINGS, FL–(Feb 20, 2015) – Nutra Pharma Corporation (OTC PINK: NPHC), a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases, announced today that Chairman and Chief Executive Officer (CEO) Rik J. Deitsch will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio / Clear Channel Atlanta Studios – 640 WGST AM this Saturday at 3:00pm ET. In this exclusive double-segment interview, Mr. Deitsch will discuss how Nutra Pharma is currently expanding its OTC retail sales of their pain therapies: Nyloxin® and Pet Pain-Away. He also discusses the clinical development of its first two therapeutic products. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: February 21, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: iHeart Radio / Clear Channel
Station: 640 WGST AM
Show: HealthTech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE 

About Nutra Pharma Corporation
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company currently markets drug products for the treatment of pain under the brands Nyloxin® and Pet Pain-Away.

About CEO Rik J. Deitsch
Nutra Pharma’s Chairman and Chief Executive Officer holds both a B.S. in Chemistry and an M.S. in Biochemistry and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic. Mr. Deitsch is the author of two books: Are You AgeWise: A Guide to Healthy Aging, and Invisible Killers: the Truth About Environmental Genocide. He is also an adjunct professor, teaching several courses for Florida Atlantic University’s College of Business and Continuing Education Department.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About HealthTech Talk Live
HealthTech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s HealthTech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com. If you’re interested in being a guest on HealthTech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

 

Starpharma Holdings Limited CEO Dr. Jackie Fairley to Be Interviewed Live on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM’s “Health Tech Talk Live” on February 14, 2015

Live Interview Airs on “Health Tech Talk Live,” Hosted by Ben Chodor, 3:00pm ET/12:00pm PT/2:00pm CT

ATLANTA, GA–(Feb 13, 2015) – Starpharma Holdings Limited (ASX: SPL) (OTCQX: SPHRY), a company that researches, develops, and commercializes dendrimer products for pharmaceutical, life-science, and agrochemical applications announced today that Chief Executive Officer (CEO), Dr. Jackie Fairley will be interviewed live on iHeart Radio’s Health Tech Talk Live hosted by Ben Chodor and broadcast nationwide on iHeart Radio/ Clear Channel Atlanta Studios – 640 WGST AM this Saturday at 3:00pm ET. In this exclusive double-segment interview, Dr. Fairley will discuss VivaGel®, the company’s development of the world’s first antiviral condom (the VivaGel® condom) which was recently launched in Australia by Starpharma’s partner, Ansell. Dr Fairley will also talk about Starpharma’s current US Phase III clinical trials of VivaGel® for the prevention of recurrent bacterial Vaginosis as well as its development of the clinical trial of the company’s improved version of cancer drug docetaxel (Taxotere). The Company’s product, DEP™ docetaxel is a dendrimer-enhanced nanoparticle formulation which is currently in a Phase I clinical trial in cancer patients. DEP™ docetaxel has shown a number of benefits compared to the commercial version of docetaxel, Taxotere® and this platform delivery technology can be used to improve other pharmaceuticals as well. Starpharma also applies its proprietary dendrimers to improve the performance of agrochemical products such as glyphosate (the active ingredient in Roundup®) and has a series of partnerships with leading industry players. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: February 14, 2015
Start Time: 3:00pm ET | 12:00pm PT | 2:00pm CT (U.S.)
Network: iHeart Radio/ Clear Channel
Station: 640 WGST AM
Show: HealthTech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE

About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX: SPL) (OTCQX: SPHRY) is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma’s underlying technology is built around dendrimers — a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. Starpharma has three core development programs: VivaGel® portfolio, DEP™ drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma’s lead products are based on VivaGel® (SPL7013, astodrimer sodium), a proprietary dendrimer. VivaGel® formulated as a mucoadhesive gel and delivered vaginally is under clinical development for the management and prevention of bacterial vaginosis (BV). Starpharma has also signed separate license agreements with Ansell Limited (ASX: ANN) and Okamoto Industries Inc., (TSE: JP3192800005) to market a value-added, VivaGel® condom. The VivaGel® condom is available for purchase in Australia under Ansell’s Lifestyles® Dual Protect™ brand. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, which is the world’s second largest condom market.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. A number of dendrimer-enhanced, or DEP™ versions of existing drugs are under development. The most advanced of these is DEP™ docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®) which is in clinical development. In preclinical studies DEP™ docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel).

In agrochemicals, Starpharma has a series of partnerships with leading industry players, as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

Starpharma’s headquarters and research facilities are located in Melbourne, Australia. Starpharma principally consists of two operating companies, Starpharma Pty Ltd in Australia and Dendritic Nanotechnologies, Inc. in USA, both with a comprehensive intellectual property portfolio.

Founded in 1996, Starpharma listed on the Australian Securities Exchange in 2000 (ASX: SPL). Starpharma securities also trade in the US under the American Depository Receipts (ADR) program, and are listed on the OCTQX platform (OTCQX: SPHRY). OTCQX is the premium tier of the US Over-the-Counter (OTC) marketplace, providing non-US companies with a visible cross-listing to access US investors, without the duplicative regulatory costs required of listing on a traditional US exchange.

About CEO Dr. Jackie Fairley B.Sc., B.V.Sc. (Hons), MBA

Jackie Fairley has 25 years of operational experience in the pharmaceutical and biotechnology industries working as a CEO since 2000. Prior to that she held business development, licensing and general management roles with companies including CSL and Faulding (now Hospira).

In 2006, Jackie was appointed CEO of ASX-listed biotechnology company Starpharma Holdings. Under her leadership, the company has been promoted to the ASX300, has developed several new and valuable commercial applications for its proprietary polymer technology and signed a number of strategically important commercial deals with companies including Astra Zeneca, Okamoto and Ansell. Starpharma has also significantly strengthened its institutional shareholder base, attracting investment from major European, US and Asian funds.

Jackie holds first class honours degrees in Science (pharmacology and pathology) and Veterinary Science from Melbourne University and was a practicing veterinary surgeon prior to joining CSL in 1989. Whilst at CSL she obtained an MBA from the Melbourne Business School, where as top student in her final year, she was the recipient of the prestigious Clemenger Medal. Jackie is also a Graduate of the Australian Institute of Company Directors.

In addition to her role at Starpharma, Jackie has served on the Board of the Melbourne Business School since 2010 and sits on the Investment Committee of Mark Carnegie’s Innovation Fund. She also sits on a number of specialist Government advisory committees.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more information visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About HealthTech Talk Live
HealthTech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s HealthTech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on HealthTech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2766291
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2766293

Interview Press/ Media  
Matthew BIRD
President
1-800-PublicRelations
+1 (917) 409-8211
matt.bird@1800pr.com
www.1800pr.com

LEAGUE CEO and Founder Michael Serbinis to Be Interviewed Live on iHeart Radio / Clear Channel Atlanta Studios – 640 WGST AM’s “Health Tech Talk Live” on January 24, 2015

Live Interview Airs on “HealthTech Talk Live,” Hosted by Ben Chodor, 3:30pm ET/12:30pm PT/2:30pm CT

TORONTO, ON–(Jan 23, 2015) – iHeart Radio’s Health Tech Talk Live announced today that LEAGUE CEO and Founder, Michael Serbinis, will be interviewed by host Ben Chodor. Serbinis previously founded global digital eReading company Kobo which sold to Rakuten for $315M and DocSpace which sold to Critical Path for $568M. Serbinis will talk about why the healthcare industry is ripe for change, how consumers will disrupt institutionally-driven care, and how his world-class team will transform our approach to preventative health.

The interview will be broadcasted nationwide on iHeart Radio/Clear Channel Atlanta Studios — 640 WGST AM this Saturday at 3:30pm ET. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: January 24, 2015
Start Time: 3:30pm ET | 12:30pm PT | 2:30pm CT (U.S.)
Network: iHeart Radio / Clear Channel
Station: 640 WGST AM
Show: HealthTech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE

About LEAGUE
LEAGUE is the future of health. The digital health and wellness platform is designed to help people live healthier, happier lives — every day. The LEAGUE platform will help people connect with a league of professionals dedicated to helping them reach their health and wellness goals through personalized insights, programs and recommendations. The platform is set to launch in early 2015. Healthcare professionals and consumers interested in participating in the company’s beta program can find more information at www.JoinLEAGUE.com.

About CEO and Founder Michael Serbinis
Michael Serbinis is the CEO and Founder of LEAGUE. He is a visionary entrepreneur who has built transformative technology platforms across several industries.

Most recently Michael was the founder and CEO of Kobo, a digital reading company that burst onto the publishing scene in 2009, driving $110M in sales in its first year. Under Michael’s leadership, Kobo became the only global competitor to Amazon’s Kindle with 20-million customers in 190 countries. Michael sold Kobo to Japanese Internet giant Rakuten for $315M in 2012.

Prior to Kobo, Michael founded and sold cloud storage pioneer DocSpace for $568M in 2000 to Critical Path, a global provider of messaging services, which ran one-third of the world’s email. Michael also developed network routing technology at Microsoft, and search engine technology at Zip2, the latter later sold to Altavista for $300M.

Michael is currently the founder of Three Angels Capital, a member of the Board of the Perimeter Institute for Theoretical Physics, the Board of the Creative Destruction Lab, the Board of Trustees at the Ontario Science Centre, and is a member of YPO. He holds a Bachelor of Science degree in Engineering Physics from Queens University and a Masters of Science in Industrial Engineering from the University of Toronto. Once upon a time, Michael developed a quantum cryptography system, and a high temperature superconductor propulsion system that won Gold at the Intel International Science & Engineering Fair, and numerous other awards, sponsorships and jobs from NASA, Rockwell Aerospace and Intel.

About iHeart Radio/ Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About Health Tech Talk Live
HealthTech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s HealthTech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on Health Tech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2754328
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2754331

Interview  Press/ Media Contact:
Matthew BIRD
President
1-800-PublicRelations, Inc.
+1 (917) 409-8211
matt.bird@1800pr.com
www.1800pr.com

eCaring, Inc. CEO Robert M. Herzog to Be Interviewed Live on iHeart Radio/Clear Channel Atlanta Studios – 640 WGST AM’s “HealthTech Talk Live” on January 17, 2015

Live Interview Airs on “HealthTech Talk Live,” Hosted by Ben Chodor, 3:30pm ET/12:30pm PT/2:30pm CT

NEW YORK, NY–(Jan 17, 2015) – eCaring, Inc., a company that helps keep people out of the hospital by generating essential real time health care data from the home, announced today that Chief Executive Officer (CEO) Robert M. Herzog will be interviewed live on iHeart Radio’s HealthTech Talk Live hosted by Ben Chodor and broadcasted nationwide on iHeart Radio/Clear Channel Atlanta Studios – 640 WGST AM this Saturday at 3:30pm ET.

In this exclusive double-segment interview, Mr. Herzog will discuss the company’s unique cloud-based system which integrates significant behavioral, clinical and medication adherence data to manage and monitor seniors and people with chronic conditions. The system has been proven to reduce emergency room and hospital visits as well as hospital readmissions, saving $300-$500 per patient per month. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: January 17, 2015
Start Time: 3:30pm ET | 12:30pm PT | 2:30pm CT (U.S.)
Network: iHeart Radio / Clear Channel
Station: 640 WGST AM
Show: HealthTech Talk Live
Host: Ben Chodor
iHeart Radio Live Stream: CLICK HERE

About eCaring
eCaring keeps people out of the hospital by generating essential real time health care data from the home. Our unique cloud-based system integrates significant behavioral, clinical and medication adherence data to manage and monitor seniors and people with chronic conditions. That information is filtered for care managers and providers, hospitals and health plans, generating actionable alerts that enable timely interventions which keep small problems in the home from leading to big ones in the hospital. A single platform manages all conditions, providing a unique new source of major health care data. The results are more efficient allocation of resources, improved information sharing, and reduced overall cost of care.

About CEO and Founder Robert M. Herzog
Robert is a pioneer in applying emerging technologies to unique business problems, and has worked extensively and successfully both as an entrepreneur and as senior executive with startup companies such as Motionbox, Diva, ON2 Corp, Softcom, Granite Films and City Winery, major corporations including JPMorgan Chase, Cahners Communications and the Sarnoff Research Center, and not-for-profits including New Jersey Appleseed and Ecotrust.

While working for the mayor of NYC, he was the creator and Director of New York City’s Energy Office. He has also taught public school and is an author and filmmaker. He graduated from Williams College and has a Master’s from the New School.

Robert’s interest and involvement in home-based healthcare emerged several years ago when he was deeply involved in the home and extended care of his mother Grace. The issues both she and he encountered ensuring that she received proper treatment gave him the initial understanding of the problems eCaring was subsequently designed to solve.

About iHeart Radio/Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more Information Visit: http://www.iheart.com/live/talk-radio-640-wgst-6066/?autoplay=true&pname=15153&campid=play_bar&cid=main.html.

About HealthTech Talk Live
HealthTech Talk Live broadcasts live weekly on iHeart Radio / Clear Channel nationwide from 640 WGST AM Atlanta, 3:00pm – 4:00pm EST every Saturday. Host Ben Chodor interviews the front-page emerging health tech innovators and titans about the latest in digital health technology, human ingenuity, bio-tech medical advancements and health tech capital market trends. Learn how the experts use risk management techniques and clinical trials to build fully diversified portfolios and what it takes to put up big board earnings from making people healthier. It’s a fast moving, high-energy show… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s HealthTech Talk Live. Visit iHeart Radio’s HealthTech Talk Radio Show or visit www.HealthTechTalk.com.

If you’re interested in being a guest on HealthTech Talk Live radio show, please contact 1800PublicRelations at support@1800pr.com “ATTN: Health Tech Talk Guest Inquiry.”

Herborium Group, Inc. CEO Dr. Agnes P. Olszewski Ph.D., to Be Interviewed on Clear Channel – iHeart Business Talk Radio’s “The Trader’s Network” on January 17th, 2015

Live Interview Airs on The Trader’s Network Radio Show, Hosted by Michael Yorba, 1:00pm ET/10:00am PT/12:00pm CT

FORT LEE, NJ–(Jan 16, 2015) – Herborium Group, Inc. (OTC PINK: HBRM), a novel Botanical Therapeutics® company focused on developing, licensing, and marketing of proprietary, botanical based medicines targeting unmet medical needs, announced today that Chief Executive Officer (CEO) Dr. Agnes P. Olszewski Ph.D. will be interviewed live tomorrow by host Michael Yorba on Clear Channel – iHeart Business Talk Radio’s “The Trader’s Network” Show. In this exclusive interview, Dr. Olszewski will discuss how the company’s innovative business model successfully addresses growing demand of consumers and healthcare professionals to access safe, efficacious, yet safe and all natural medicinal options for treatment and prevention of selected diseases and health concerns. The company’s unprecedented growth in 2014 as well as plans and opportunities for 2015 will also be discussed. U.S. Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: January 17, 2015
Start Time:  1:00pm ET |10:00am PT | 12:00pm CT (U.S.)
Network: Clear Channel – iHeart
Station: DFW 1190AM
KFXR Show: The Trader’s Network
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About Herborium Group, Inc.
Herborium Group, Inc. is a novel Botanical Therapeutics® company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs. The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health concerns.

The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The potential for this market assesses for over $125 billion in the USA, Canada and UK alone.

This new market is presently positioned for exponential growth since it represents a compelling response to changing needs of a healthcare sector. For the industry, botanical therapeutics® provide a value added approach based on product differentiation, higher profit margins, and intellectual property protection with a lower risk and regulatory burden and lower cost. Nutraceuticals (supplements) face increasing FDA and market scrutiny, with massive competitive pressures. To meet the needs of this new growing market opportunity for a diverse spectrum of botanically based drugs, along with complementary and non-traditional therapies; Herborium introduces its own Botanical Therapeutics® defined as “bridge products,” an emerging category of natural medicines with clinically and scientifically validated efficacy and safety.

Botanical Therapeutics® represents benefits and attributes of both aforementioned traditional sectors. Botanical Therapeutics® bring the intellectual property value, posology, clinical validation and rapid market entry while maintaining a safety profile of botanical ingredients and offering the benefits of preventive medicine and cost containment. For its own Botanical Therapeutics® the Company adopts clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its proprietary therapeutic candidates from so called “ethnic” medicinal sources such as Traditional Chinese Medicine (TCM) with initial confirmatory data and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western and progressive global markets. This strategy serves to mitigate risk in the product development and marketing strategies. The Company secured a pipeline of botanical ingredient based products in the areas of Dermatologic, Women’s Health and Men’s Health including selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Short term product portfolio also includes all herbal Energy and Stress Management formula free of caffeine, sugar, Vit. B complex and amino acids. The longer-term pipeline includes Prostate Health (BPH) and Liver Diseases, as well as product extensions in existing product categories and the anti-infectious product candidate focused on antibiotic resistant infections. Herborium Managements represents a unique blend of expertise with over 50 years of successful business dealings in marketing healthcare and consumer products, an exceptional track record in pharmacology and drug development, clinical testing and regulatory affairs in the US and Europe, supported by high standards, know how in herbal science and formulation and global outreach. Herborium presently sells its products in the United States, the United Kingdom, Canada and continental Europe through a network of distributors, specialty retailers, and e-commerce. With initial seed investment brought to the Company by Friends and Family and a small professional round, the Company has developed and deployed a solid and innovative business model that already brings rapidly growing revenues and is ideally positioned for exponential growth in the near future. Down economic times are actually realizing an additional pressure on the sector, and both consumers and insurance companies look for safer and more affordable healthcare options.

About CEO Dr. Agnes P. Olszewski Ph.D.
Western medical science has revolutionized the treatment of diseases worldwide, offering a science-based, clinically tested approach and enabling patients to routinely manage diseases that used to be considered a death sentence. But centuries before Anthony Leeuwenhoek spotted bacteria through a microscope, traditional communities in Asia, South America, Africa and even Europe were using herbal compounds to provide relief for medical conditions and promote wellness. Dr. Agnes P. Olszewski, a U.S. citizen who grew up in Europe and gained extensive experience with traditional medicine as a business consultant in Asia, is in a unique position to appreciate the benefits of a blended approach to wellness that draws on the wisdom of both modern and ancient traditions. That’s what led her to found Herborium Group (HBRM), a publicly traded Botanical Therapeutics® company, since 2006.

With both a PhD and an MBA, Dr. Olszewski developed her passion for providing all-natural alternatives and complementary botanical ingredients-based therapies that blend science and nature during an over 20-year strategic management and consulting career that included extensive work in the development and marketing of consumer products, including botanical medicines, beauty and health supplements and nutrition products in the U.S., Europe and China. Her experience includes work on a high-profile biotechnology joint venture in China, where she cultivated relationships with key Chinese business and government officials. Dr. Olszewski also served as Director of the Institute for International Business at Seton Hall University and as Professor of Marketing and International Business prior to founding Herborium.

Since launching Herborium Group, Dr. Olszewski and her team have focused on developing products that combine the best Western and traditional medicine have to offer, meeting unmet wellness needs in the U.S. and Europe. Leveraging the treasure trove of traditional medicines that have been proven effective over the centuries and applying modern scientific standards in development and testing, Herborium currently offers a range of Botanical Therapeutics® that address a variety of conditions, including acne and the controlling symptoms of rosacea, men’s and women’s sexual health, energy and stress management and in an foreseeable future, Prostate Health.

Presently, the company’s flagship product is AcnEase®, all herbal dermatologic that treats the root cause of acne — an overproduction of sebum (skin oil) by sebaceous glands, which leads to localized inflammation and scarring — instead of just acne the symptoms. AcnEase® tablets, a proprietary herbal compound that restores balance and skin health, is up to 96% effective in treating acne and the controlling symptoms of rosacea and works for people who suffer from acne of any type at any age, regardless of gender, skin type and color of complexion. Herborium’s Women and Men Sexual formulas and Energy & Stress Management formula are in line to market.

In addition to developing botanical-based medicinal products, Dr. Olszewski is also passionate about educating the public about the benefits — and potential drawbacks — of natural medicines. She is a member of the GLG Council and a frequent speaker and writer on the topics of integrated and personalized medicine, natural remedies, wellness and prevention, nutraceutical products and global marketing strategies in a sector. Find out more about Dr. Olszewski and the Herborium Group at www.herborium.com.

About Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. www.clearchannel.com.

About The Traders Network Show
For the past six years “The Traders Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 6am – 7:30am and 2pm – 3pm CT, Monday-Friday. Host Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps the audience asking for more… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Traders Network Show. To inquire about being a guest on this show please contact “1800pr” at www.1800PublicRelations.com.

CONTACT INFORMATION

Ascendant Solutions, Inc. President and CFO Mark S. Heil To Be Interviewed Live on Clear Channel — iHeart Business Talk Radio’s “The Trader’s Network” — January 17, 2015

Live Interview Airs on The Trader’s Network Radio Show, Hosted by Michael Yorba, 1:30pm ET/10:30am PT/12:30pm CT

LETHBRIDGE, AB–(Jan 16, 2015) – Ascendant Solutions, Inc. (OTC PINK: ASDS), a value-oriented investment firm focused on successfully acquiring, managing and growing community-based pharmacies in the Southwest Region, announced today that President and Chief Financial Officer Mark S. Heil will be interviewed live tomorrow by host Michael Yorba on Clear Channel – iHeart Business Talk Radio’s “The Trader’s Network” Show. In this exclusive interview, Mr. Heil will discuss how the company is executing its growth strategy by acquiring well-run, independent pharmacies in the southwestern U.S. Ascendant shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: January 17, 2015
Start Time:  1:30pm ET | 10:30am PT | 12:30pm CT (U.S.)
Network: Clear Channel – iHeart
Station: DFW 1190AM
KFXR Show: The Trader’s Network
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About Ascendant Solutions, Inc.
Ascendant Solutions, Inc. (“Ascendant”) is a value-oriented investment firm focused on successfully acquiring, managing and growing community-based pharmacies in the Southwest Region of the United States.

Acquired in 2004, the company’s flagship pharmacy, Dougherty’s Pharmacy, located at Preston Road and Royal Lane in Dallas is recognized as one of the largest independent retail pharmacies in the United States. A beloved Dallas institution since 1929, Dougherty’s Pharmacy has focused on pharmaceutical excellence and personal service. Dougherty’s Pharmacy is the area’s oldest, largest, and most recognized full-service pharmacy in the region.

Ascendant’s healthcare division, Dougherty’s Holdings, Inc., continues to grow based on strategic acquisitions of well-run, independent pharmacies in the Southwest as highlighted by recent purchases of pharmacies in Humble and El Paso, Texas.

Ascendant currently has approximately $43 million in net operating loss carryforwards to use against future taxable income. These carryforwards expire between 2019 and 2032 providing future tax savings, enhancing free cash flow resulting in additional debt service capabilities for Ascendant.

About President and CFO Mark S. Heil
Mr. Heil was named President of Ascendant in April 2014, and he has served as Chief Financial Officer of Ascendant and certain of its subsidiaries since 2007. In 2012, he was appointed President of the Company’s healthcare subsidiary, Dougherty’s Holdings, Inc. and he also serves on the Board of Directors of Dougherty’s Holdings. Mr. Heil has significant experience in finance and accounting matters having served in various executive positions, including various chief financial officer roles and chief operating officer capacities along with consulting experience in the executive services field. Prior to joining Ascendant, Mr. Heil served as a consulting associate at Tatum LLC, which provides financial consulting and executive services to its clients. Previous to Tatum, he held various Chief Financial Officer positions at The Loomis Agency, a full service advertising company and at American Excelsior Company, a manufacturing and distribution company. In addition, he held the position of Chief Operating Officer of American Excelsior’s Earth Science Division during his tenure with this firm. Mr. Heil began his career in the audit division of KPMG. He graduated from the University of Texas with a BBA in Accounting and also served on the board of directors of American Excelsior Company. He is a Certified Public Accountant in the State of Texas and is a member of the Financial Executives International (FEI).

About Clear Channel: Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. www.clearchannel.com.

About The Traders Network Show: For the past six years “The Traders Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 6am – 7:30am and 2pm – 3pm CT, Monday-Friday. Host Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps audience asking for more… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Traders Network Show. To inquire about being a guest on this show please contact “1800pr” at www.1800PublicRelations.com.

CONTACT INFORMATION

CEO Gerald Commissiong of Amarantus to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW 1190AM

Today at 1:05pm CST / 2:05 pm EST on The Traders Network With Host Michael Yorba

SAN FRANCISCO, CA–(Feb 19, 2014) – Amarantus Bioscience Holdings, Inc. (OTCBB: AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio’s The Traders Network.

All investors, analysts, industry professionals and prospective customers that are interested to learn more about Amarantus Bioscience, its goals and recent developments are invited to tune in and listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

The interview will air today, Tuesday, February 18, 2014 at 1:05pm U.S. CST / 11:05am PST / 2:05pm EST on Clear Channel DFW 1190AM.

Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true
Time: 1:05pm CST | 11:05pm PST | 2:05pm EST (U.S.)
Date: February 19, 2014
Network: Clear Channel
Station: DFW 1190 AM KFXR
Host: Michael Yorba

About Clear Channel: Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. www.clearchannel.com.

About Michael Yorba: Mr. Yorba is the founder of Yorba Media and featured host on Clear Channel. For the past six years he has been integrally involved with producing and hosting a daily talk show called Commodity Classics, and The Traders Network.

From the fast action of the trading pit… to the power brokers making the headlines… Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps investors and consumers asking for more… The Traders Network stays ahead of the curve by featuring leading market and business professionals, sophisticated technology, and the analytics needed to identify the most lucrative investment strategies. Successful performance depends on finding the right opportunities. So… shift your thinking and join us as we deliver “tomorrow’s ideas today” on Clear Channel’s The Traders Network Monday – Friday from 1:00pm – 3:00pm CST live after Glenn Beck.

About Amarantus: Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine a phase 2b ready indication for Parkinson’s Levodopa induced dyskinesia and Adult ADHD The Company has an exclusive worldwide license to the Lymphocyte Proliferation test (“LymPro Test®”) for Alzheimer’s disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson’s disease (“NuroPro”) and the discovery of neurotrophic factors (“PhenoGuard”). For further information please visit www.Amarantus.com, or connect with the Company on FacebookLinkedInTwitter and Google+.

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements.” These forward-looking statements generally are identified by the words believes,” project,” expects,” anticipates,” estimates,” intends,” strategy,” plan,” may,” will,” would,” will be,” will continue,” will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

www.1800PublicRelations.com PR Event

CONTACT INFORMATION

Press/Media 


Matthew Bird

1-800-PublicRelations.com, Inc.

+1 (917) 409-8211

matt.bird@1800pr.com

www.1800pr.com

 

Visit Our BlogVisit Our BlogVisit Our Blog